Preliminary experience with yttrium-90-labeled Rituximab (chimeric anti-CD20 antibody) in patients with relapsed and refractory B-cell NHL - a prospective trial

被引：0
|
作者：
Thakral, P. [1 ]
Lata, S. [1 ]
Singla, S. [1 ]
Sharma, A. [1 ]
Bal, C. [1 ]
Malhotra, A. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP690
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [21] Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with Rituximab, a chimeric Anti-CD20 monoclonal antibody
    Soda, R
    Costanzo, A
    Cantonetti, M
    Orlandi, A
    Bianchi, L
    Chimenti, S
    ACTA DERMATO-VENEREOLOGICA, 2001, 81 (03) : 207 - 208
  • [22] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Øystein Fluge
    Olav Mella
    BMC Neurology, 9
  • [23] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Fluge, Oystein
    Mella, Olav
    BMC NEUROLOGY, 2009, 9
  • [24] Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: A report of 7 cases
    Fierro, MT
    Savoia, P
    Quaglino, P
    Novelli, M
    Barberis, M
    Bernengo, MG
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (02) : 281 - 287
  • [25] Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Witzig, TE
    Gordon, LI
    Cabanillas, F
    Czuczman, MS
    Emmanouilides, C
    Joyce, R
    Pohlman, BL
    Bartlett, NL
    Wiseman, GA
    Padre, N
    Grillo-López, AJ
    Multani, P
    White, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) : 2453 - 2463
  • [26] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [27] Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
    Heinzerling, L
    Dummer, R
    Kempf, W
    Schmid, MH
    Burg, G
    ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 374 - 378
  • [28] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [29] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [30] Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody (rituximab) for relapsed or refractory non-Hodgkins lymphoma.
    Turner, JH
    Martindale, A
    Claringbold, PG
    Boucek, J
    Leahy, MF
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 115P - 116P
12345